IL6 and COVID-19: Since tocilizumab, but not siltuximab, has been shown from meta-analyses to be effective in patients hospitalised with COVID-19 (32), blocking trans-presentation and IL-6-induced TH17 polarization would be particularly crucial to prevent severe to critical disease progression.